23
Feb
2010
Posted in I - Series D, Q - 1Q10, R - NORTH EAST, X - Opthalmology, X - THx Delivery, XX - MA
EyeGate Pharma (Wlatham, MA) a clinical-stage company focused on a non-invasive iontophoresis drug delivery system for ocular therapeutics, closed a $22.6M Series D financing. Participants include Natixis Private Equity, Emerging Capital, Ventech, Innoven Partners and Medicis Capital.